Patents by Inventor Kamalraj Thiyagarajan

Kamalraj Thiyagarajan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK
    Patent number: 11673886
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: June 13, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
  • 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK
    Publication number: 20220356179
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: June 17, 2021
    Publication date: November 10, 2022
    Inventors: Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
  • 5-membered and bicyclic heterocyclic amides as inhibitors of rock
    Patent number: 11078197
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: August 3, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
  • 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK
    Publication number: 20210147406
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 11, 2018
    Publication date: May 20, 2021
    Inventors: Peter W. Glunz, Vladimir Ladziata, Indawati De Lucca, George O. Tora, Tarun Kumar Maishal, Raghuram Tangirala, Kamalraj Thiyagarajan
  • Spiro-fused cyclic ureas as inhibitors of rock
    Patent number: 10787450
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: September 29, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Mandar Shrikrishna Bodas, Pravin Sudhakar Shirude, Sharanabasappa Patil, Tarun Kumar Maishal, Kamalraj Thiyagarajan, Kumaresan Chinnakotti, Peter W. Glunz
  • Tricyclic rho kinase inhibitors
    Patent number: 10654860
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: May 19, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wu Yang, Peter W. Glunz, Rajeev S. Bhide, Kamalraj Thiyagarajan
  • SPIRO-FUSED CYCLIC UREAS AS INHIBITORS OF ROCK
    Publication number: 20190300528
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 3, 2019
    Inventors: Rajeev S. Bhide, Mandar Shrikrishna Bodas, Pravin Sudhakar Shirude, Sharanabasappa Patil, Tarun Kumar Maishal, Kamalraj Thiyagarajan, Kumaresan Chinnakotti, Peter W. Glunz
  • TRICYCLIC RHO KINASE INHIBITORS
    Publication number: 20190276466
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: November 29, 2017
    Publication date: September 12, 2019
    Inventors: Wu Yang, Peter W. Glunz, Rajeev S. Bhide, Kamalraj Thiyagarajan
  • Fused pyridines as kinase inhibitors
    Patent number: 10174044
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 8, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Susheel Jethanand Nara, Carolyn Diane Dzierba, John E. Macor, Joanne J. Bronson, Rajamani Ramkumar, Tarun Kumar Maishal, Maheswaran Sivasamban Karatholuvhu, Soodamani Thangavel, Kamalraj Thiyagarajan
  • FUSED PYRIDINES AS KINASE INHIBITORS
    Publication number: 20180141956
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: April 4, 2016
    Publication date: May 24, 2018
    Inventors: Susheel Jethanand Nara, Carolyn Diane Dzierba, John E. Macor, Joanne J. Bronson, Rajamani Ramkumar, Tarun Kumar Maishal, Maheswaran Sivasamban Karatholuvhu, Soodamani Thangavel, Kamalraj Thiyagarajan